Free Trial
NASDAQ:UBX

UNITY Biotechnology Q3 2024 Earnings Report

UNITY Biotechnology EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

UNITY Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

UNITY Biotechnology Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Monday, November 4, 2024
Conference Call Time
12:00AM ET

UNITY Biotechnology Earnings Headlines

Buffett, Gates and Bezos Dumping Stocks
The world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.tc pixel
UBX Unity Biotechnology, Inc. - Seeking Alpha
See More UNITY Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like UNITY Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on UNITY Biotechnology and other key companies, straight to your email.

About UNITY Biotechnology

UNITY Biotechnology (NASDAQ:UBX), a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

View UNITY Biotechnology Profile

More Earnings Resources from MarketBeat